

**To:** 5.1.2e | 5.1.2e | 5.1.2e | @rivm.nl]  
**From:** 5.1.2e  
**Sent:** Fri 3/26/2021 3:27:04 AM  
**Subject:** RE: Infectious Disease Surveillance and Emergency Preparedness - Netherlands  
**Received:** Fri 3/26/2021 3:27:26 AM  
[BlueDot VaccineAdministration6.pdf](#)

Hello 5.1.2e

Here is our latest Focus Report - **Global Updates of COVID-19 Vaccine Administration and Research - spotlight on COVID-19 vaccine passports**. In this report, we highlight

5.1.2a

- (2) The most recent evidence of pre-existing natural immunity from previous infection
- (3) Reason of AstraZeneca's vaccine suspension in many countries and it's current situation
- (4) A detailed spotlight on COVID-19 vaccine passports
- (5) Updates on the most recent results of AstraZeneca vaccine's Phase 3 trial in the U.S., and updates for candidates under Phase 2/3 or Phase 3 trial

Please do let us know if you found this report to be useful. Looking forward to hearing from you.

Regards,

5.1.2e

5.1.2e / BlueDot

5.1.2e / [www.bluedot.global](http://www.bluedot.global)

---

**From:** 5.1.2e  
**Sent:** Monday, March 22, 2021 12:03 AM  
**To:** 5.1.2e | @rivm.nl  
**Subject:** RE: Infectious Disease Surveillance and Emergency Preparedness - Netherlands

Hello 5.1.2e

Following up to share our latest Focus Report on COVID 19 Variants. This report includes:

- An update on the global spread of the three current Variants of Concern (VoC)
- Highlight several variants that have emerged
- Summarize scientific evidence available thus far on the clinical impact of these VoC
- Provide an outlook on the COVID-19 situation in Denmark (a country with high genomic surveillance capacity) based on a synthesis of its domestic spread of the VoCs, epidemiological indicators, implemented control measures, vaccination efforts and related public sentiment

Hope you find it useful. Please let us know if you have any questions/feedbacks for us.

Regards,

5.1.2e

BlueDot

5.1.2e | [www.bluedot.global](http://www.bluedot.global)

---

**From:** 5.1.2e  
**Sent:** Monday, March 15, 2021 12:12 AM  
**To:** 5.1.2e | @rivm.nl  
**Subject:** Infectious Disease Surveillance and Emergency Preparedness - Netherlands

Good morning 5.1.2e

5.1.2e [REDACTED] at RIVM, your perspective on the challenges faced by Netherlands during ID outbreaks is extremely valuable, which encouraged me to reach out to you.

5.1.2e [REDACTED] at **BlueDot**, a physician led Infectious Diseases surveillance company based in Toronto, Canada.

**OUR AIM:** Backed by 17 years of extensive research and Artificial Intelligence we support governments in saving time, safeguarding their populations and economy by timely predicting the import and export of Infectious Diseases and extending accurate risk assessments.

We have been extensively supporting Global Health Agencies like **US CDC and PHAC (Public Health Agency of Canada), Taiwan CDC and all ASEAN member states** in building strong resilience against COVID and any future Infectious Disease Outbreaks.

Learning your priorities and current challenges will be extremely valuable for us. Would you be willing to spare 30 mins this/next week for a brief meeting?

Looking forward to hearing from you!

Regards,

5.1.2e [REDACTED]

BlueDot

5.1.2e [REDACTED]

[www.bluedot.global](http://www.bluedot.global)